Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Depreciation & Amortization (CF): 2020-2025

Historic Depreciation & Amortization (CF) for Tango Therapeutics (TNGX) over the last 5 years, with Sep 2025 value amounting to $555,000.

  • Tango Therapeutics' Depreciation & Amortization (CF) fell 7.50% to $555,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 million, marking a year-over-year decrease of 4.49%. This contributed to the annual value of $2.5 million for FY2024, which is 3.52% up from last year.
  • According to the latest figures from Q3 2025, Tango Therapeutics' Depreciation & Amortization (CF) is $555,000, which was down 11.20% from $625,000 recorded in Q2 2025.
  • Tango Therapeutics' 5-year Depreciation & Amortization (CF) high stood at $675,000 for Q2 2024, and its period low was $200,000 during Q3 2021.
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $600,000 (2024), whereas its average is $610,636.
  • In the last 5 years, Tango Therapeutics' Depreciation & Amortization (CF) skyrocketed by 120.08% in 2022 and then decreased by 7.50% in 2025.
  • Over the past 5 years, Tango Therapeutics' Depreciation & Amortization (CF) (Quarterly) stood at $259,000 in 2021, then soared by 120.08% to $570,000 in 2022, then rose by 7.89% to $615,000 in 2023, then dropped by 2.44% to $600,000 in 2024, then declined by 7.50% to $555,000 in 2025.
  • Its last three reported values are $555,000 in Q3 2025, $625,000 for Q2 2025, and $622,000 during Q1 2025.